NEUMANN MARK (EVP, Chief Commercial Officer) received a stock award from INTRA-CELLULAR THERAPIES, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/4/2025ACC: 0000950170-25-013762
Officer· EVP, Chief Commercial Officer
Since Oct 2018
+29.02K
Net shares
Net buyer
$600.6K
Total sold
0
Open market trades
0B · 0S
3
Total transactions
33.74K acquired · 4.73K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+11.02K
Price / share
—
Trade value
—
% of position
37.1%
1/31/2025
29.70K→40.72K
Common Stock
Direct
Shares
−4.73K
Price / share
$127.00
Trade value
$600.58K
% of position
11.6%
1/31/2025
40.72K→35.99K
Total
Net shares
+6.29K
Net value
-$600.58K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/31/2025 | A · Award | +11.02K | — | — | 37.1% | 29.70K | 40.72K |
| Common Stock Direct | 1/31/2025 | F · Tax Withholding | −4.73K | $127.00 | $600.58K | 11.6% | 40.72K | 35.99K |
| Total | +6.29K | -$600.58K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
22.73K shares
Shares
+22.73K
Strike price
Held after
22.73K
Exercisable
—
2/3/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock22.73K shares | 2/3/2025 | A · Award | +22.73K | — | 22.73K |